Skip to Content


Treatment for Insomnia

Neurocrine Biosciences Announces Resubmission Status of Indiplon

The Company Also Announces Conference Call and Webcast to Present Fourth Quarter and Year-End 2004 Financial Results

SAN DIEGO, February 07, 2005 -- Neurocrine Biosciences (NASDAQ:NBIX) announced today that it completed its meeting with the FDA regarding the resubmission of its indiplon immediate release and modified release New Drug Applications (NDAs). The company announced that based on the January 26, 2005 meeting with the FDA, it is now expecting to resubmit the immediate release (IR) capsules NDA at end of 1st Quarter / beginning of the 2nd Quarter 2005, followed by the Modified Release (MR) tablets NDA also in the 2nd Quarter 2005.

"Our recent meeting with the FDA regarding the issues related to our NDA submissions was very productive and contained no surprises. The FDA reviewed our reformatting plans and agreed that such plans were sufficient to allow proper FDA navigation of the document. Based on this meeting, we are moving ahead to resubmit our electronic New Drug Applications (NDAs) as quickly as possible, said Gary Lyons, President & CEO of Neurocrine Biosciences. "We will take advantage of the timing of the resubmission of the MR NDA to also incorporate data from the recently completed MR clinical study (404) into the submission rather than amending the application during review. Results of the 404 modified release clinical study in adults with chronic insomnia will be released in mid February. During our fourth quarter conference call we will provide guidance to 2005 earnings and also answer questions relating to our recent regulatory discussions and activities to ensure continued progress toward launch."

Neurocrine Biosciences, Inc. also announced today that the Company will report fourth quarter and year-end 2004 financial results after the NASDAQ market closes on Thursday, February 10, 2005. Neurocrine will also host a live conference call and Webcast to discuss its year-end results and provide a Company update Thursday afternoon, February 10, 2005 at 4:30 PM Eastern Standard Time (EST) / 1:30 PM Pacific Standard Time (PST). The live Conference Call can be accessed by dialing 1-800-905-0392 (U.S.) or 785-832-0201 (International) and using the Conference ID# NBIX. The call can also be accessed via the Webcast through the Company's website at

If you are unable to attend the Webcast and would like further information on this announcement please contact Claudia Jones or Elizabeth Foster in the Investor Relations Department at Neurocrine Biosciences at 858-617-7600. A replay of the Conference Call will be available by dialing 1-800-839-3607 (US) or 402-220-2970 (International) and will be archived until Thursday, February 24, 2005.

Neurocrine Biosciences, Inc. is a product-based biopharmaceutical company focused on neurological and endocrine diseases and disorders. Our product candidates address some of the largest pharmaceutical markets in the world including insomnia, anxiety, depression, diabetes, multiple sclerosis, irritable bowel syndrome, eating disorders, pain, and autoimmunity.
For more information, please visit

Posted: February 2005

Related Articles

Indiplon (NBI-34060) FDA Approval History

More News Resources

Subscribe to our Newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of in your inbox.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.